Shares of iRadimed Corp. (NASDAQ:IRMD) saw an uptick in trading volume on Wednesday . 127,083 shares traded hands during trading, an increase of 58% from the previous session’s volume of 80,295 shares.The stock last traded at $17.28 and had previously closed at $17.28.

Several brokerages have recently commented on IRMD. Zacks Investment Research cut iRadimed Corp. from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 5th. Roth Capital restated a “buy” rating on shares of iRadimed Corp. in a report on Tuesday, May 3rd.

The firm has a market cap of $184.95 million and a P/E ratio of 24.90. The company has a 50 day moving average of $19.51 and a 200 day moving average of $18.25.

iRadimed Corp. (NASDAQ:IRMD) last issued its earnings results on Friday, July 29th. The company reported $0.24 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.21 by $0.03. The business had revenue of $9.90 million for the quarter, compared to the consensus estimate of $9.60 million. The business’s revenue was up 30.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.16 earnings per share. On average, equities analysts expect that iRadimed Corp. will post $0.92 EPS for the current fiscal year.

In other news, Director Monty K. Allen sold 2,100 shares of iRadimed Corp. stock in a transaction that occurred on Monday, June 13th. The stock was sold at an average price of $20.44, for a total transaction of $42,924.00. Following the completion of the transaction, the director now directly owns 4,375 shares in the company, valued at approximately $89,425. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Steven M. Nardi sold 2,096 shares of iRadimed Corp. stock in a transaction that occurred on Tuesday, August 16th. The stock was sold at an average price of $17.11, for a total value of $35,862.56. Following the transaction, the vice president now owns 1,996 shares of the company’s stock, valued at $34,151.56. The disclosure for this sale can be found here.

An institutional investor recently bought a new position in iRadimed Corp. stock. Russell Frank Co bought a new stake in iRadimed Corp. (NASDAQ:IRMD) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 95,112 shares of the company’s stock, valued at approximately $2,675,000. Russell Frank Co owned approximately 0.86% of iRadimed Corp. at the end of the most recent quarter.

IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.